10x Genomics vs Alamar Biosciences
Side-by-side comparison of AI visibility scores, market position, and capabilities
Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience, and immunology.
About
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabling researchers to analyze gene expression across thousands of individual cells simultaneously—a capability that transformed cell biology, immunology, and cancer research. The Visium Spatial Gene Expression platform extended this to map gene expression within intact tissue architecture.\n\n10x Genomics' instruments and consumables are used by leading academic research centers, pharmaceutical companies, and translational medicine teams to profile the cellular composition of tumors, map the nervous system, characterize immune responses, and develop cell therapies. The company reported full-year 2025 revenue of $642.8 million, up from $610.8 million in 2024, and guides to $600–$625 million for 2026 amid cautious biotech funding conditions.\n\nThe company is transitioning toward a broader multi-omics portfolio including ATAC-seq, protein detection, and spatial multi-omics, while defending market position against competition from Parse Biosciences, Vizgen, and others. Despite near-term funding headwinds in academic markets, 10x Genomics remains a foundational infrastructure provider for the cell atlas era of biology.
Alamar Biosciences develops the NULISA proteomics platform for ultrasensitive protein biomarker detection from minimal sample volumes; enables early disease detection and drug development research;
About
Alamar Biosciences is a Fremont, California-based life sciences company founded in 2020 with a focus on advancing proteomics through ultrasensitive biomarker detection technology. The company's flagship platform, NULISA (Nucleic acid-Linked Immuno-Sandwich Assay), enables researchers to simultaneously measure hundreds of protein biomarkers from very small sample volumes — including blood, cerebrospinal fluid, and other biological matrices — with sensitivity orders of magnitude beyond conventional assays like ELISA. This capability is critical for detecting disease-associated proteins at very early stages before symptoms manifest.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.